The global Minimal Residual Disease (MRD) Market is projected to reach USD 2.55 billion by 2029, rising from USD 1.43 billion in 2024, at a CAGR of 12.2% during the forecast period. This growth is driven by the rising incidence of cancer and hematological malignancies, expanding government awareness initiatives, and an increasing number of collaborations and research partnerships across the diagnostics ecosystem.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=215386038
Market Insights & Key Trends
Growing Adoption of IGRA Tests
A major technological shift reshaping the MRD testing landscape is the accelerated development of Interferon Gamma Release Assay (IGRA) tests. These tests offer significant advantages over tuberculin skin tests (TSTs), particularly:
- Higher accuracy and sensitivity, especially in individuals vaccinated with BCG
- Single-visit completion, improving patient compliance
- Greater scalability through automation and improved platforms
As precision diagnostics become a global priority, IGRAs are gaining traction for their reliability and adaptability in both high-burden and resource-constrained environments. This shift is expected to attract new market entrants and push established players to increase investment in advanced MRD technologies.
Market Segmentation Analysis
By Product
- Assay Kits & Reagents (fastest-growing)
- Instruments
The assay kits & reagents segment leads in growth due to frequent purchases and expanding use in routine diagnostics. Demand for instruments also continues to rise, supported by the need for high-precision diagnostic platforms in high-burden regions.
By Technology
- Polymerase Chain Reaction (PCR) — largest share in 2023
- Flow Cytometry
- Next-Generation Sequencing (NGS)
PCR remains dominant because of its ease of use, wide availability of assay kits, high sensitivity, and cost-effectiveness. Its strong clinical applicability keeps it the most widely used MRD detection technology.
By Application
- Hematological Malignancies — 66% share in 2023
- Solid Tumors
- Multiple Myeloma
- Others
Hematological malignancies constitute the largest segment, driven by the rising prevalence of leukemia and lymphoma and the growing need for continuous disease monitoring.
By End Users
- Hospitals & Specialty Clinics — largest share in 2023
- Diagnostic Laboratories — fastest-growing
- Academic & Research Institutes
- Others
Hospitals dominate due to access to advanced diagnostic infrastructure and skilled professionals. Diagnostic laboratories are expanding rapidly as they increasingly adopt high-throughput MRD testing technologies.
Regional Highlights
The market is segmented into:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- GCC Countries
North America held the largest market share in 2023, supported by high leukemia and lymphoma prevalence, an advanced healthcare ecosystem, a strong presence of national diagnostic laboratories, and widespread access to cutting-edge MRD technologies.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=215386038
Competitive Landscape
Major players include:
F. Hoffmann-La Roche Ltd. (Switzerland), Labcorp Inc. (US), Guardant Health (US), Sysmex Corporation (Japan), NeoGenomics (US), Adaptive Biotechnologies (US), ArcherDX (US), Asuragen (US), ARUP Laboratories (US), Bio-Rad Laboratories (US) and others.
Company Profiles
F. Hoffmann-La Roche Ltd.
Roche led the MRD testing market in 2023, driven by its comprehensive product offerings and strategic approach to innovation. Despite relatively lower R&D investment compared to peers, the company’s expansive global distribution network—spanning 180 countries—strengthens its market dominance. Roche’s partnerships and collaborations further enhance its integrated diagnostic solutions.
Labcorp Inc.
Labcorp stands as the second-largest MRD testing provider, backed by a vast diagnostic portfolio and a robust presence across North America, Europe, the Middle East, Africa, and Asia Pacific. The company focuses heavily on R&D and has expanded its capabilities through strategic acquisitions such as AtlantiCare and OmiSeq. Its extensive distribution network supports continued global market expansion.
Guardant Health
Guardant Health is a leader in precision oncology, specializing in advanced liquid biopsy technologies. Its flagship Guardant Reveal blood test detects circulating tumor DNA (ctDNA) to identify MRD in early-stage cancers such as lung, colorectal, and breast cancer. With a strong presence in the US and growing traction across Europe, APAC, and the Middle East, the company plays a pivotal role in advancing personalized cancer diagnostics.
